Plan to improve malaria control towards its elimination in Mesoamerica;Plan de mejoramiento del control de la malaria hacia su eliminación en Mesoamérica

Salud Publica de Mexico

Volumn 53, Issue SUPPL. 3, 2011, Pages

  Rodríguez, Mario Henry ^a   Betanzos Reyes, Angel Francisco ^a   Marenco, José Antonio ^b   Polanco, Jorge ^b   Bautista, Kim ^b   Miranda, Adolfo ^b   Sánchez López, Arturo ^b   Torres, Paúl ^b   Alemán, Jaime ^b   Ordóñez, Manuel ^b   Salgado Elvir, Laura J ^b   Martín Sinclair, Ivan ^b   Carrillo, Willy ^b   Marín, Rodrigo ^b   Garcés, José Luis ^b   González, Óscar ^b   Victoria, Carlos ^b   Hernández Ávila, Juan E ^b   Méndez Galván, Jorge ^b   González Cerón, Lilia ^b   Rodríguez Ramírez, Américo David ^b   Vázquez Martínez, María Guadalupe ^b   Olguín Bernal, Héctor ^b   Colín, Nohemí ^b   Arredondo Jiménez, Juan Ignacio ^b   more..

^a INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^b Instituto Nacional de Salud Pública ^*  (Mexico)

Author keywords

Elimination; Latin america; Malaria; Regional health planning; Risk management; Stratification

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; PRIMAQUINE;

ANIMAL; ARTICLE; CENTRAL AMERICA; CONSUMER; DEVELOPING COUNTRY; DISEASE CARRIER; ECONOMICS; ENDEMIC DISEASE; HEALTH CARE PLANNING; HEALTH PROMOTION; HEALTH SERVICE; HUMAN; INTERNATIONAL COOPERATION; LABORATORY; MALARIA; MEXICO; MOSQUITO; MOTIVATION; ORGANIZATION AND MANAGEMENT; PUBLIC HEALTH; RISK MANAGEMENT; STATISTICS;

ANIMALS; ANTIMALARIALS; CENTRAL AMERICA; CHLOROQUINE; CONSUMER PARTICIPATION; DEVELOPING COUNTRIES; ENDEMIC DISEASES; GOALS; HEALTH PLAN IMPLEMENTATION; HEALTH PROMOTION; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; INSECT VECTORS; INTERNATIONAL COOPERATION; LABORATORIES; MALARIA; MEXICO; MOSQUITO CONTROL; PRIMAQUINE; PUBLIC HEALTH; RISK MANAGEMENT;

EID: 84858691070     PISSN: 00363634     EISSN: 16067916     Source Type: Journal    
DOI: None     Document Type: Article

References (87)

1. Bill and Melinda Gates Foundation. Strategy Lifecycle Overview and Guide. Seattle: Bill and Melinda Gates Foundation, 2008.
2. World Health Organization. Informal consultation on malaria: setting up the WHO agenda. WHO global malaria Program. Geneva: WHO, 2006.
3. World Health Organization. Sixth Report of the Expert Committee on malaria. WHO/MAL/180; June 28 1956.
4. Méndez-Galván JF, Betanzos-Reyes AF, Velázquez-Monroy O, Tapia-Conyer R. Guía para la implementación y demostración de alternativas sostenibles de control integrado de la malaria en México y América Central. Definición del Universo de los Proyectos Demostrativos. Secretaría de Salud de México. Centro Nacional de Vigilancia Epidemiológica y Control de Enfermedades. Proyecto DDT/GEF: UNEP/CENAVECE/SSA/OPS/CCA/GEF. Primera edición 2004, ISBN: 970-721-243-8. [Consultado 2009 agosto-noviembre] Disponible en: http://www.mex.ops-oms.org/publicaciones
5. Proyecto de Integración y Desarrollo. Sistema Mesoamericano de Salud Pública, 2009. Secretaría de Relaciones Exteriores y Secretaría de Salud de México. [Consultado 2009 agosto-noviembre] Disponible en: www.proyectomesoamerica.org
6. World Health Organization. Global malaria control and elimination: Report of a technical review. Geneva: WHO, 2008.
7. Organización Panamericana de la Salud. Salud de las Américas, 2007. Volumen por país. PAHO, 2007. [Consultado agosto-noviembre 2009]. Disponible en: [Available at: http://www.paho.org/hia/vol2paises.html]
8. Organización Panamericana de la Salud. Información de la Salud y Análisis. Situación de Salud en las Américas. Indicadores Básicos 2008. Washington, DC: PAHO, 2008.
9. Pan American Health Organization. Health Situation in the Americas. Basic Indicators, 2009. Washington, DC: PAHO, 2009.
10. World Health Organization. World malaria report 2008. Geneva: WHO, 2008. ISBN 978 92 4 156369 7; WHO/HTM/MAL/GMP/2008.1.
11. Pan American Health Organization. Malaria Morbidity Trend in the Americas. Baseline in 2000; Data for 2006 and 2007; Target for 2010 & 2015 (No. of cases). Washington, DC: PAHO, 2008.
12. Sáenz LB. Evaluación del Programa mesoamericano de Vigilancia Epidemiológica Regional (RG-T1224).ATN/SF-9935-RG. Reporte Final. Octubre, 2008. Inter-American Development Bank. Representación en El Salvador.
13. Bill and Melinda Gates Foundation. Strategy Lifecycle Overview and Guide. Seattle: Bill and Melinda Gates Foundation, 2008.
14. Feachem-Richard GA, the Malaria Elimination Group. Shrinking the Malaria Map: A Guide on Malaria Elimination for Policy Makers. San Francisco: The Global Health Group. Global Health Sciences. University of California, 2009. [Consultado 2010 julio-agosto] Disponible en: www.malariaeliminationgroup.org
15. World Health Organization. Global malaria control and elimination: Report of a technical review. Geneva: WHO, 2008.
16. World Health Organization. Malaria elimination. Field manual for low and moderate endemic countries. Geneva, World Health Organization, 2007. ISBN 978 92 4 159608 4; WHO/HTM/MAL/2007.765 6. [Consultado 2010 julio-agosto] Disponible en: http://www.who.int/malaria/docs/elimination/malariaelimination_bd.pdf.
17. World Health Organization. Guidelines on the elimination of residual foci of malaria transmission. EMRO Technical Publication Series 3. Geneva: WHO, 2007.
18. Rodríguez-López MH, Loyola-Elizondo EG, Betanzos-Reyes AF, Villarreal-Treviño C, Bown DN. Control Focal del Paludismo. Tratamiento focal usando quimioprofiláxis y rociado intradomiciliar con insecticida para el control del paludismo en el sur de México. Gaceta Med Mex 1994; 130:313-319.
19. Hernández-Avila JE, Rodríguez MH, Betanzos-Reyes AF, Danis-Lozano R, Méndez-Galván JF, Velázquez-Monroy OJ, et al. Determinant factors for malaria transmission on the coast of Oaxaca State, the main residual transmission focus of Mexico. Salud Pub Mex 2006; 405-417.
20. Chanon KE, Méndez-Galván JF, Galindo-Jaramillo JM, Olguin-Bernal H, Borja-Aburto VH. Cooperative actions to achieve malaria control without the use of DDT. Int J Hyg Environ Health 2003; 20:387-394.
21. Greenwood BM. Impact of culture and environmental changes on epidemiology and control of malaria and babesiosis: the microepidemiology of malaria and its importance to malaria control. Trans R Soc Trop Med Hyg 1989; 58: 533-542.
22. Carter R, Mendis, de Sousa APK, Mendis KN. Clustering of malaria infections within an endemic population: risk of malaria associated with the type of housing construction. Am J Trop Med Hyg 1991; 45:77-85.
23. Danis-Lozano R, Rodríguez MH, Betanzos-Reyes AF, Hernández-Avila JE, González-Cerón L. Individual risk factors for Plasmodium vivax infection in the residual malaria transmission focus of Oaxaca, Mexico. Salud Pub Mex 2007; 49:199-209.
24. Rodríguez MH, Betanzos-Reyes AF, Hernández-Avila JE, Méndez-Galván JF, Danis-Lozano R, Altamirano-Jiménez A. The Participation of secondary clinical episodes in the epidemiology of vivax malaria during pre-and postimplementation of focal control in the State of Oaxaca, Mexico. Am J Trop Med Hyg 2009; 80:889-895.
25. Peterson I, Borell LN, El-Sadr W, Teklechimanot A. Individual and household level factors associated with malaria incidence in a highland region of Ethiopia: A multilevel analysis. Am J Trop Med Hyg 2009; 80:103-111.
26. Coleman M, Coleman M, Mabaso ML, Mabuza AM, Kok G, Coetzee M. Household and microeconomic factors associated with malaria in Mpumalanga South Africa. Trans R Soc Trop Med Hyg 2009; 1258, doi:10,1016/j.trstmh.2009.07.010.
27. Rincón-Romero ME, Londoño JE. Mapping malaria risk using environmental and anthropic variables. Rev Bras Epidemiol 2009; 12:338-354.
28. Rodulfo H, De Donato M, Mora R, González L, Contreras CE. Comparison of the diagnosis of malaria by microscopy, immunochromatography and PCR in endemic areas of Venezuela. Braz J Med Biol Res 2007; 40:535-543.
29. Rosas Aguirre AM, Llanos Zavalaga LF, Trelles de Belaunde M. Cost-effectiveness ratio of using rapid tests for malaria diagnosis in the Peruvian Amazon. Rev Panam Salud Publica 2009;25(5):377-388
30. Suárez-Mutis MC, Cuervo P, Leoratti FM, Moraes-Avila SL, Ferreira AW, Fernandes O, et al. Cross sectional study reveals a high percentage of asymptomatic Plasmodium vivax infection in the Amazon Rio Negro area, Brazil. Rev Inst Med Trop Sao Paulo 2007; 49:159-164.
31. Coura JR, Suárez-Mutis M, Ladeia-Andrade S. A new challenge for malaria control in Brazil: asymptomatic Plasmodium infection-a review. Mem Inst Oswaldo Cruz 2006; 101:229-237.
32. Lubell Y, Reyburn H, Mbakilwa H, Mwangi R, Chonya S, Whitty CJ. The impact of response to the results of diagnostic tests for malaria: costbenefit analysis. BMJ 2008; 336:202-205.
33. Lubell Y, Reyburn H, Mbakilwa H, Mwangi R, Chonya K, Whitty CJ. The cost-effectiveness of parasitologic diagnosis for malaria-suspected patients in an era of combination therapy. Am J Trop Med Hyg 2007; 77:128-132.
34. Stauffer WM, Cartwright CP, Olson DA, Juni BA, Taylor CM, Bowers SH, et al. Diagnostic performance of rapid diagnostic tests versus blood smears for malaria in US clinical practice. Clin Infect Dis 2009; 49:908-913.
35. Bisoffi Z, Sirima BS, Angheben A, Lodesani C, Gobbi F, Tinto H, et al. Rapid malaria diagnostic tests vs. clinical management of malaria in rural Burkina Faso: safety and effect on clinical decisions. A randomized trial. Trop Med Int Health 2009; 14:491-498.
36. Chanda P, Castillo-Riquelme M, Masiye F. Cost-effectiveness analysis of the available strategies for diagnosing malaria in outpatient clinics in Zambia. Cost Eff Resour Alloc 2009 7:5.
37. González-Cerón L, Rodríguez MH, Betanzos AF, Abadía A. Efficacy of a rapid test to diagnose Plasmodium vivax in symptomatic patients of Chiapas, Mexico. Salud Pub Mex 2005; 47:282-287.
38. Steenkeste N, Incardona S, Chy S, Duval L, Ekala MT, Lim P, et al. Towards high-throughput molecular detection of Plasmodium: new approaches and molecular markers. Malar J 2009; 8:86.
39. Corran P, Coleman P, Riley E, Drakeley C. Serology: a robust indicator of malaria transmission intensity? Trends Parasitol 2007; 23:575-582.
40. World Health Organization. Guidelines for the treatment of malaria. Global Malaria Programme. World Health Organization, 2010. Geneva, 2nd edition. ISBN 978 92 4 154792 5. WHO/HTM/MAL/2006.1108. [Consultado 2010 julio-agosto] Disponible en: http://whqlibdoc.who.int/publications/2010/9789241547925_eng.pdf.
41. Calzada JE, Samudio F, Bayard V, Obaldia N, de Mosca IB, Pascale JM. Revising antimalarial drug policy in Central America: experience in Panama. Trans R Soc Trop Med Hyg 2008;102(7):694-698.
42. Carmona-Fonseca J, Alvarez G. Plasmodium vivax malaria: treatment of primary attacks with primaquine, in three different doses, and a fixed dose of chloroquine, Antioquia, Colombia, 2003-2004. Biomedica 2006; 26:353-365.
43. Baird JK, Hoffman SL. Primaquine therapy for malaria. Clin Infect Dis 2004; 39:1336-1345.
44. Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg 2006; 75:402-415.
45. Baird JK. Resistance to therapies for infection by Plasmodium vivax. Clin Microbiol Rev 2009; 22:508-534.
46. Baird JK, Schwartz E, Hoffman SL. Prevention and treatment of vivax malaria. Curr Infect Dis Rep 2007; 9:39-46
47. Galappaththy GN, Omari AA, Tharyan P. Primaquine for preventing relapses in people with Plasmodium vivax malaria. Cochrane Database Syst Rev 2007;24; (1):CD004389.
48. Leslie T, Mayan I, Mohammed N, Erasmus P, Kolaczinski J, Whitty CJ, et al. A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of Plasmodium vivax in Northwest Frontier Province, Pakistan. PLoS One 2008;6;3(8):e2861
49. Carmona-Fonseca J, Maestre A. Prevention of Plasmodium vivax malaria recurrence: efficacy of the standard total dose of primaquine administered over 3 days. Acta Trop 2009; 112:188-192.
50. Kitchener S, Nasveld P, Bennett S, Torresi J. Adequate primaquine for vivax malaria. J Travel Med 2005;12(3):133-135.
51. Bunnag D, Karbwang J, Thanavibul A, Chittamas S, Ratanapongse Y, Chalermrut K, et al. High dose of primaquine in primaquine resistant vivax malaria. Trans R Soc Trop Med Hyg 1994; 88:218-219.
52. Silachamroon U, Krudsood S, Treeprasertsuk S, Wilairatana P, Chalearmrult K, Mint HY, et al. Clinical trial of oral artesunate with or without high-dose primaquine for the treatment of vivax malaria in Thailand. Am J Trop Med Hyg 2003; 69:14-18.
53. Krudsood S, Tangpukdee N, Wilairatana P, Phophak N, Baird JK, Brittenham GM, et al. High-dose primaquine regimens against relapse of Plasmodium vivax malaria. Am J Trop Med Hyg 2008; 78:736-740.
54. White NJ. The role of anti-malarial drugs in eliminating malaria. Malar J 2008; 11; 7 Suppl 1:S8.
55. Garfield RM, Vermund SH. Changes in malaria incidence after mass drug administration in Nicaragua. Lancet 1983; 2:500-503.
56. Khantikul N, Butraporn P, Kim HS, Leemingsawat S, Tempongko MA, Suwonkerd W. Adherence to antimalarial drug therapy among vivax malaria patients in northern Thailand. J Health Pop Nutr 2009;27:4-13.
57. Leslie T, Rab MA, Ahmadzai H, Durrani N, Fayaz M, Kolaczinski J, et al. Compliance with 14-day primaquine therapy for radical cure of vivax malaria-a randomized placebo-controlled trial comparing unsupervised with supervised treatment. Trans R Soc Trop Med Hyg 2004; 98:168-173.
58. Sreehari U, Mittal PK, Razdan RK, Dash AP, Ansari MA. Impact of etofenprox (Vectron® 20 WP) indoor residual spray on malaria transmission. Indian J Med Res 2009; 129: 593-598.
59. Bukirwa H, Yau V, Kigozi R, Filler S, Quick L, Lugemwa M, et al. Assessing the impact of indoor rtesidual spraying on malaria morbidity using a sentinel site surveillance system in Western Uganda. Am J Trop Med Hyg 2009; 81:611-614.
60. Doke PP, Sathe RS, Chouhan SP, Bhosale AS. Impact of single round of indoor residual spray with lambda-cyhalotrin 10% WP on Plasmodium falciparum infection in Akola district, Maharashtra State. J Commun Dis 2000; 32:190-200.
61. Sharp BL, Ridl FC, Govender D, Kuklinski J, Kleinschmidt I. Malaria vector control by indoor residual insecticide spraying on the tropical island of Bioko, Equatorial Guinea. Malar J 2007 2; 6:52.
62. Sharma SK, Upadhyay AK, Haque MA, Padhan K, Tyagi PK, Batra CP, et al. Village-scale evaluation of mosquito nets treated with a tablet formulation of deltamethrin against malaria vectors. Med Vet Entomol 2005; 19:286-292.
63. Kroeger A, González M, Ordóñez-González J. Insecticide-treated materials for malaria control in Latin America: to use or not to use? Trans R Soc Trop Med Hyg 1999; 93(6):565-570.
64. Duchon S, Bonnet J, Marcombe S, Zaim M, Corbel V. Pyrethrum: A Mixture of natural pyrethrins has potential for malaria vector control. J Med Entomol 2009; 46:516-522.
65. N'guessan R, Knols BG, Pennetier C, Rowland M. DEET microencapsulation: a slow-release formulation enhancing the residual efficacy of bed nets against malaria vectors. Trans R Soc Trop Med Hyg 2008;102(3):259-262.
66. Kroeger A, Aviña A, Ordónez-González J, Escandón C. Community cooperatives and insecticide-treated materials for malaria control: a new experience in Latin America. Malar J 2002 15; 1:15.
67. Mathanga DP, Luman ET, Campbell CH, Silwimba C, Malenga G. Integration of insecticide-treated net distribution into routine immunization services in Malawi: a pilot study. Trop Med Int Health 2009; 14:792-801.
68. Hanson K, Kikumbih N, Armstrong-Schellenberg J, Mponda H, Nathan R, Lake S, et al. Cost-effectiveness of social marketing of insecticidetreated nets for malaria control in the United Republic of Tanzania. Bull WHO 2003; 81:269-276.
69. Killeen GF, Tami A, Kihonda J, Okumu FO, Kotas ME, Grundmann H, et al. Cost-sharing strategies combining targeted public subsidies with private-sector delivery achieve high bednet coverage and reduced malaria transmission in Kilombero Valley, southern Tanzania. BMC Infect Dis 2007 25; 7:121.
70. Mueller DH, Wiseman V, Bakusa D, Morgah K, Daré A, Tchamdja P. Cost-effectiveness analysis of insecticide-treated net distribution as part of the Togo Integrated Child Health Campaign. Malar J 2008; 7:73.
71. Wacira DG, Hill J, McCall PJ, Kroeger A. Delivery of insecticide-treated net services through employer and community-based approaches in Kenya. Trop Med Int Health 2007; 12:140-149.
72. Atkinson JA, Bobogare A, Fitzgerald L, Boaz L, Appleyard B, Toaliu H, et al. A qualitative study on the acceptability and preference of three types of long-lasting insecticide-treated bed nets in Solomon Islands: implications for malaria elimination. Malar J 2009; 8:119.
73. Magris M, Rubio-Palis Y, Alexander N, Ruiz B, Galván N, Frias D, et al. Community-randomized trial of lambdacyhalothrin-treated hammock nets for malaria control in Yanomami communities in the Amazon region of Venezuela. Trop Med Int Health 2007; 12:392-403.
74. Eisele TP, Keating J, Littrell M, Larsen D, Macintyre K. Assessment of insecticide-treated bednet use among children and pregnant women across 15 countries using standardized national surveys. Am J Trop Med Hyg 2009; 80:209-214.
75. Chanda E, Masaninga F, Coleman M, Sikaala C, Katebe C, Macdonald M, et al. Integrated vector management: The Zambian experience. Mal J 2008;7:164.
76. Arredondo-Jimenez JI, Rodríguez MH, Brown DN, Loyola EG. Indoor low-volume insecticide sprays for the control of Anopheles albimanus in southern Mexico. Village-scale trials of bendiocarb, deltamethrin and cyfluthrin. J Am Mosq Control Assoc 1993; 9:210-220.
77. Villarreal C, Rodriguez MH, Bown DN, Arredondo-Jiménez JI. Low-volume application by mist-blower compared with conventional compression sprayer treatment of houses with residual pyrethroid to control the malaria vector Anopheles albimanus in Mexico. Med Vet Entomol 1995; 9:187-194.
78. Eliason DA, Joseph VR, Karam J. A prospective study of the effects of ultralow volume (ULV) aerial application of malathion on epidemic Plasmodium falciparum malaria: I. Study design and perspective. Am J Trop Med Hyg 1975; 24:183-187.
79. Zakus JD, Lysack CL. Revisiting community participation. Health Policy Plan 1998; 13(1):1-12.
80. Morgan-Lynn M. Community participation in health: perpetual allure, persistent challenge. Health Policy and Plan 2001; 16:221-230.
81. World Vision International, 2009. Malaria control, community systems strengthening and community-owned response: Consensus on best practice for use in the development of Global Fund Round 9 malaria proposals and National Strategy Applications. Disponible en: http://tinyurl.com/yfzabeb
82. PAHO, 2007. Prevención, Vigilancia y Control de la Malaria: Manual para líderes y agentes de salud de los pueblos indígenas y afro descendientes. Proyecto DDT/GEF: UNEP/CENAVECE/SSA/OPS/CCA/GEF. Primera edición 2007, Quito, Ecuador. [Consultado 2009 agostonoviembre] Disponible: http://www.mex.ops-oms.org/publicaciones
83. Mlozi MR, Shayo EH, Senkoro KP, Mayala BK, Rumisha SF, Mutayoba B, et al. Participatory involvement of farming communities and public sectors in determining malaria control strategies in Mvomero District, Tanzania. Tanzan Health Res Bull 2006 Sep;8(3):134-40 [Consultado 2010 julioagosto] Disponible en: http://www.bioline.org.br/request?rb06025
84. Opiyo, P, Mukabana WR, Kiche I, Mathengue E, Killeen GF, Fillinger U. An exploratory study of community factors relevant for participatory malaria control on Rusinga Island, western Kenya. Malar J 2007;24; 6:48 [Consultado 2010 julio-agosto] Disponible en: http://www.malariajournal.com/content/pdf/1475-2875-6-48.pdf
85. Developed by the Communication for Social Change Consortium. Measuring change: A guide to participatory monitoring and evaluation of communication for social Change. Edited by Ailish Byrne with Denise Gray-Felder, Jim Hunt and Will Parks. 2005. Disponible en: www.communicationforsocialchange.org; y [Consultado 2010 julio-agosto] Disponible en: http://www.communicationforsocialchange.org/pdf/measuring_change.pdf
86. Ciclo del Plasmodium vivax [Consultado 2009 noviembre 7]. Disponible en: http://www.vivaxmalaria.com/template_disease.htm
87. UN Millennium Project. Investing in Development: A Practical Plan to Achieve the Millennium Development Goals. Overview. New York: United Nations Development Programme, 2005.